Community protocol
Third-partyBPC 157: 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 60 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 6
BPC-157
Extensive rodent literature reporting tendon, ligament and gut healing effects, almost entirely from a single research group. Human trial evidence is minimal.
Overview
BPC-157 is a 15-amino-acid fragment derived from a protein found in human gastric juice. In rodent studies it has been reported to speed the healing of tendons, ligaments, muscle and gut lining. The proposed explanation is that it encourages new blood vessel growth into damaged tissue and helps cells migrate into the wound. Very little of this has been tested in humans, which is the central limitation of the compound.
BPC-157 is the sequence GEPPPGKPADDAGLV, a partial sequence of body protection compound isolated from human gastric juice. It has no known dedicated receptor. Reported mechanisms in rodent models include upregulation of VEGFR2 with downstream Akt/eNOS activation driving angiogenesis; modulation of the nitric oxide system, with reported activity against both L-NAME-induced hypertension and L-arginine-induced hypotension; increased expression of growth hormone receptor in tendon fibroblasts; upregulation of FAK-paxillin signalling promoting fibroblast migration; and interaction with dopaminergic and serotonergic systems in central models. The absence of an identified primary receptor, and the concentration of published work within one laboratory group, are the principal interpretive constraints on this literature.
Research areas
HealingMusculoskeletalGastrointestinalNeuroprotection
Community-specified data
Community dosage information
Community protocol
Third-partyBPC-157 20mg
- 01Reconstitution solution
- 2 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 30 days
- 06Bacteriostatic water
- 2 mL
- 07Bottle size
- 20 mg
- 08Bottles needed
- 2
Community protocol
Third-partyBPC157 10mg + TB500 10mg
- 01Reconstitution solution
- 2 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 60 days
- 06Bacteriostatic water
- 2 mL
- 07Bottle size
- 20 mg
- 08Bottles needed
- 3
Community protocol
Third-partyBPC157 30mg + TB500 30mg
- 01Reconstitution solution
- 3 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 60 days
- 06Bacteriostatic water
- 3 mL
- 07Bottle size
- 60 mg
- 08Bottles needed
- 1
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| 10 µg/kg intraperitoneal, daily, in rat tendon and muscle healing modelsRodent dose. Interspecies allometric scaling to a human dose is not validated for this compound and no human dose-finding study has been published. | Krivic et al., Journal of Orthopaedic Research 2006 |
| 10 ng/kg to 10 µg/kg ranges across rodent gastrointestinal modelsThe reported effective range spans three orders of magnitude across models, which limits how precisely any dose can be inferred. | Sikiric et al., Current Pharmaceutical Design 2011 |
Trial status
One completed phase 2 trial in ulcerative colitis (PL 14736) with limited published outcome data. No published phase 3 trials. Remaining evidence is preclinical.
Preclinical
CompletedLarge body of rodent work covering tendon transection, muscle crush, colitis, and NSAID-induced gastric lesion models. Predominantly from Sikiric and colleagues at the University of Zagreb.
Phase 1
CompletedSafety studies conducted as PL 14736. No serious adverse events reported in the available summaries.
Phase 2 — ulcerative colitis
TerminatedTrial of PL 14736 in inflammatory bowel disease. Development did not proceed to phase 3 and full outcome data were not published in a peer-reviewed journal.
Reported safety signals
- No published long-term human safety data exist.
- Angiogenic activity is the primary theoretical concern raised in reviews, given the role of neovascularization in tumour growth. This has not been studied directly.
- Material sold as BPC-157 is not manufactured to pharmaceutical standards and purity varies between sources.
Common questions
Why is BPC-157 only a grade C when there are so many studies?
Grading weighs study design, not study count. Nearly all BPC-157 literature is rodent work, and a large share originates from one research group, so findings have not been independently replicated at scale. Grade C reflects consistent preclinical signal with no adequately powered human trial.
What would move BPC-157 to a higher grade?
A registered, adequately powered, randomized placebo-controlled human trial with a published outcome — most plausibly in tendinopathy or inflammatory bowel disease, where the preclinical signal is strongest.
Primary sources
- 01
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease
- 02
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157
- 03
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
- 04
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →